Equity Overview
Price & Market Data
Price: $1.12
Daily Change: $0.00 / 0.00%
Range: $1.02 - $1.16
Market Cap: $65,860,256
Volume: 580,917
Performance Metrics
1 Week: -4.27%
1 Month: -21.68%
3 Months: -25.33%
6 Months: -52.94%
1 Year: -83.26%
YTD: -18.25%
Company Details
Employees: 105
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.